Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ceftolozane/tazobactam (Zerbaxa®) cannot be endorsed for use within NHS Wales for the treatment of hospital-acquired pneumonia, including ventilator‑associated pneumonia in adults. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines. |
||
|
||
Medicine details |
||
| Medicine name | ceftolozane/tazobactam (Zerbaxa®) | |
| Formulation | 1 g/0.5 g powder for concentrate for solution for infusion | |
| Reference number | 2182 | |
| Indication | For the treatment of hospital-acquired pneumonia, including ventilator‑associated pneumonia in adults |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 18/02/2020 | |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines |
||